<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068483</url>
  </required_header>
  <id_info>
    <org_study_id>CBKM120X2101</org_study_id>
    <secondary_id>2008-002652-17</secondary_id>
    <nct_id>NCT01068483</nct_id>
  </id_info>
  <brief_title>Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients</brief_title>
  <official_title>A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-man, phase I clinical research study with BKM120, a potent and highly&#xD;
      specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists&#xD;
      of a dose escalation part followed by a MTD expansion part.&#xD;
&#xD;
      Once the MTD has been defined, the MTD expansion part will be opened for enrollment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of BKM120</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BKM120</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BKM120</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tumor metabolic activity</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of BKM120</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical tumor response in patients with tumors that show PI3K pathway activation</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrium Cancer</condition>
  <arm_group>
    <arm_group_label>BKM120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation followed by dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BKM120</intervention_name>
    <arm_group_label>BKM120</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients:&#xD;
&#xD;
          -  Histologically-confirmed advanced solid tumors&#xD;
&#xD;
          -  Progressive, recurrent unresectable disease&#xD;
&#xD;
          -  World Health Organization (WHO) Performance status ≤ 2&#xD;
&#xD;
          -  No history of primary brain tumor or brain metastases&#xD;
&#xD;
        MTD Expansion part:&#xD;
&#xD;
          -  Histologically-confirmed advanced solid tumors&#xD;
&#xD;
          -  Progressive, recurrent unresectable disease&#xD;
&#xD;
          -  World Health Organization (WHO) Performance status ≤ 2&#xD;
&#xD;
          -  No history of primary brain tumor; no brain metastases unless asymptomatic and&#xD;
             clinically stable for ≥ 3 months&#xD;
&#xD;
          -  Patients with genetic or molecular alteration of the PI3K pathway&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a PI3K inhibitor&#xD;
&#xD;
          -  History of or active major depressive episode, bipolar disorder, schizophrenia, or&#xD;
             history of suicidal attempt or ideation&#xD;
&#xD;
          -  No clinically manifest diabetes mellitus (treated and/or with clinical signs)&#xD;
&#xD;
          -  No acute or chronic renal disease&#xD;
&#xD;
          -  No acute or chronic liver disease&#xD;
&#xD;
          -  No acute or chronic pancreatitis&#xD;
&#xD;
          -  No unresolved diarrhea&#xD;
&#xD;
          -  No impaired cardiac function or clinically significant cardiac diseases such as&#xD;
             ventricular arrhythmia, congestive heart failure, uncontrolled hypertension&#xD;
&#xD;
          -  No acute myocardial infarction or unstable angina pectoris within the past 3 months&#xD;
&#xD;
          -  Not pregnant or nursing and fertile patients must use barrier contraceptives&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(4)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=7084</url>
    <description>Results for CBKM120X2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid tumors</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Endometrium cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

